——– Messaggio Inoltrato ——–
| Oggetto: | Fwd: Call for Section Editors: CNS & Neurological Disorders Drug Targets Impact Factor: 2.824 |
|---|---|
| Data: | Fri, 5 Aug 2022 14:44:44 +0200 |
| Mittente: | Sergio Stagnaro <dottsergio@semeioticabiofisica.it> |
| A: | segreteria ministero sanità <segreteriaministro@sanita.it> |
Al Ministro della Salute, Roberto Speranza,
come giustifica la censura imposta alla Semeiotica Biofisica Quantistica da lei e dai suoi compagni di viaggio con il contenuto della seguente mail?
Occultare l’esistenza dei Reali Rischi Congeniti è un crimine contro l’Umanità. Fare la TQMR senza divulgarla è desolante.
Mi auguro, pertanto, che nel prossimo governo lei non figuri.
Saluti
Dr Sergio Stagnaro
90 anni, Medico di MG, pensionato dal 202i
Dr Sergio Stagnaro
Via Erasmo Piaggio 23/8,
16039 Riva Trigoso (Genoa) Italy
Phone 3888770382
Founder of Quantum Biophysical Semeiotics,
Honorary President of International Society of
Quantum Biophysical Semeiotics (SISBQ)
www.sergiostagnaro.wordpress.com
——– Messaggio Inoltrato ——–
| Oggetto: | Call for Section Editors: CNS & Neurological Disorders Drug Targets Impact Factor: 2.824 |
|---|---|
| Data: | Fri, 5 Aug 2022 12:18:18 +0500 |
| Mittente: | Editorial Office <editorial@currsmartmat.net> |
| A: | dottsergio@semeioticabiofisica.it |
CNS & Neurological Disorders Drug Targets
August 5, 2022
Dr. S. Stagnaro
International Society of Quantum Biophysical Semeiotics
Lancenigo
Italy
Italy
Dear Dr. S. Stagnaro,
This is a Call for the Appointment of Section Editors, to the journal “CNS & Neurological Disorders Drug Targets (CNSNDDT), (Impact Factor 2.824)”. This journal is in its 21st volume and has been abstracted/indexed in several prominent indexing agencies including Science Citation Index Expanded™, SciSearch®, Journal Citation Reports/Science Edition, Scopus etc. The Journal publishes high quality reviews and research papers focusing on hot topics, besides thematic issues in the field of the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.
Considering your contributions in the field, and based on your published article entitled “Inherited real risk of schizophrenia: Pathogenesis, bedside diagnosis and primary prevention”, we feel that your field of interest is related to the field of the journal, and you would be a valuable addition to its Board as a Section Editor. We therefore request your permission to communicate with you further on this matter.
The scope of the “CNS & Neurological Disorders – Drug Targets” covers all areas of neurological and central nervous system (CNS) disorders, including, but not limited to:
1. 5-HT and Anxiety
2. 5-HT Receptors and Their Function
3. Acetylcholinesterase Inhibitors
4. Analgesics
5. Anticonvulsants
6. Antidepressants
7. Antipsichotics
8. ATP-Mediated Cytotoxicity
9. Attention Deficit Hyperactivity Disorder
10. Benzodiazepines
11. Bipolar Disorder
12. Blood-Brain Barrier
13. Brain Disorders
14. Brain Hemorrhage
15. Brain-Derived Neurotrophic Factor
16. Brain Signalling Molecules
17. Cannabinoids
18. Clinical Neuroscience
19. CNS Axon Regeneration
20. CNS Diseases
21. Cognitive Neuroscience Section
22. Dementia
23. Depressive Disorders
24. Dopamine and Drug Addiction
25. Dopamine Receptors and Brain Function
26. Epilepsy
27. GABA Receptors
28. Glutamate Receptors
29. Melatonin
30. Metabotropic Glutamate Receptor
31. Migraine
32. Mood Stabilizers
33. Multiple Sclerosis
34. Neurodegenerative Diseases
35. Neurodevelopment
36. Neuroinflammation
37. Neurogenesis
38. Neuronal Nicotinic Receptor
39. Neuropeptide
40. Neuroprotection
41. Neuropsychopharmacology
42. Neurosteroids
43. Neurotoxicity
44. Neurotransmitter
45. Noradrenaline
46. Obsessive-Compulsive Disorder
47. Oxidative Stress and Neurodegenerative Diseases
48. Oxytocin and Eating Disorder
49. Psychotic Disorders
50. Schizophrenia
51. Serotonin
52. Statins and the Brain
53. Therapeutics of Alzheimer’s Disease
54. Traumatic Brain Injury
If you feel that this is something that would interest you, please let us know and we will send you further details regarding the role and benefits of the Section Editors.
We look forward to receiving your positive response.
Sincerely,
Q.Malik
Editorial Manager
La Voce di SergioStagnaro 
Rispondi